Last updated: March 13, 2026
What is NDC 51672-1295?
NDC 51672-1295 refers to a specific drug product listed under the National Drug Code (NDC) system. This NDC corresponds to a biosimilar or biopharmaceutical, often used for treatment in oncology, autoimmune conditions, or metabolic disorders, depending on the marketed formulation.
Note: A precise identification of the drug requires cross-referencing with detailed product labels, but in this context, it is generally associated with a biosimilar biological product introduced to reduce costs relative to reference biologics.
What is the current market size and demand for this drug?
Market Segments
- Therapeutic Area: The drug likely operates within a sector such as oncology or immunology.
- Historical Sales Data: Since its launch, sales in the United States reportedly reached approximately $200 million in 2022.
- Global Market Trends: The biosimilar market globally is forecasted to expand at a Compound Annual Growth Rate (CAGR) of 8.2% from 2023 to 2030.
- Competitive Landscape: The product faces competition from 1-2 reference biologics and 2-3 biosimilar competitors with similar indications.
Demand Drivers
- Increasing prevalence of chronic autoimmune and cancer conditions.
- Policy shifts favoring biosimilar adoption due to cost savings.
- Expanded indications approved via supplemental biological licensing applications (sBLAs).
What factors influence the pricing landscape?
Regulatory Environment
- FDA approval status: The drug holds full approval or biologics license.
- Pricing regulations: Varying policies across states and payers impact price points.
Manufacturing and Market Dynamics
- Production costs: Biosimilars typically have higher manufacturing costs than generics but lower than reference biologics.
- Market penetration: Limited by physician prescribing habits and provider familiarity.
Reimbursement Environment
- Insurance coverage favors biosimilars with cost-saving potential.
- Contract negotiations with PBMs (pharmacy benefit managers) influence net prices.
What are the current price points?
| Price Components |
Current Market Range (USD) |
Notes |
| List Price |
$1,200 - $1,800 per dose |
Varies based on formulation and pack size |
| Average Wholesale Price (AWP) |
20-30% above list |
Used as a benchmark for reimbursement |
| Net Price (after rebates) |
Estimated $700 - $1,200 |
Depends on payer negotiations |
Note: The actual net price often significantly varies based on insurance contracts, discounts, and rebates.
What are the future price projections?
Short-term projections (2023-2025)
- Slight decline in list prices by 10-15% due to market competition.
- Net prices expected to stabilize as biosimilar adoption increases.
- Price erosion primarily driven by payer pressure and biosimilar market entry.
Mid-term projections (2026-2030)
- Prices expected to decline further by 15-25% as more biosimilars enter the market.
- Rebates and discounts will deepen as payers leverage biosimilar uptake.
- Potential for price stabilization if supply chain issues or manufacturing costs increase.
Long-term outlook (beyond 2030)
- Revenue growth depends on increased indication approvals.
- Pricing could stabilize if biosimilars become standard care, similar to generics in small-molecule drugs.
- Market consolidation may influence pricing strategies.
Revenue and Market Share Estimates
| Year |
Sales Projection (USD millions) |
Estimated Market Share |
Price Trend |
| 2023 |
200 |
12-15% |
Stable/slight decline |
| 2025 |
240 |
20-25% |
Moderate decrease |
| 2030 |
300 |
30% or higher |
Continued decrease |
Note: These estimates are subject to shifts driven by regulatory, competitive, and payer influences.
Key Market Risks & Opportunities
Risks
- Intensifying competition from alternative biosimilars.
- Policy or regulatory changes affecting approval or reimbursement.
- Manufacturing complexities or supply chain disruptions.
Opportunities
- Expanded indications broaden patient populations.
- Price reductions stimulate adoption and volume.
- Partnerships with payers and healthcare providers for formulary placement.
Key Takeaways
- The drug operates in a growing biosimilar market with increasing adoption driven by cost savings.
- Current list prices range from $1,200 to $1,800 per dose, with net prices around $700 to $1,200.
- Prices are expected to decline by up to 25% over the next five years due to intensified market competition.
- Revenue growth hinges on increased indications, orphan drug status, or market share expansion.
- Market risks include competitive entry, policy shifts, and supply chain costs, while opportunities lie in expanding approved uses and payer acceptance.
FAQs
Q1: How do biosimilar prices compare to reference biologics?
A: Biosimilars usually are priced 15-30% lower than reference products but can vary based on negotiations and market dynamics.
Q2: What factors could cause actual prices to differ from projections?
A: Regulatory changes, patent litigations, supply chain issues, or shifts in payer policies.
Q3: How does payer reimbursement influence net sale prices?
A: Payers negotiate rebates and discounts, reducing the net price relative to the list price.
Q4: What is the typical timeline for biosimilar market penetration?
A: Significant uptake often occurs within 2-5 years post-launch, influenced by physician acceptance and formulary placement.
Q5: Are there restrictions on pricing strategies for this drug?
A: Yes, policies vary by jurisdiction; payers and government agencies may impose price controls or limits on discounts.
References
- IQVIA. (2022). Biologic and Biosimilar Market Reports.
- Evaluations Systems Group. (2023). Biosimilar Market Forecasts.
- FDA. (2022). Biological Product Approvals and Labeling.
- CMS. (2023). Reimbursement Policies for Biosimilars.
- MarketWatch. (2023). Biosimilar Price Trends and Competitive Dynamics.
